AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company formed in January 2013 following separation from Abbott, celebrates launch in Ukraine. AbbVie product portfolio includes medicines for treatment of several of the world’s most serious diseases.

With arich, 125-year heritage of developing pharmaceuticals, AbbVie combines thefocus and passion of a leading-edge biotech with the expertise and structure ofa long-established pharmaceutical leader. A global enterprise that servespatients in more than 170 countries, AbbVie was launched with an estimated $18billion in annual revenues and a strong commitment to creating shareholdervalue through long-term growth potential and the continuation of the company’shistory of shareholder dividends.

AbbVieentered NYSE on January, 2. The company’s leaders, employees from more than 40countries and patients participated in the ceremony.

“AbbVielaunches with an outstanding portfolio, a solid pipeline and enthusiasticpeople who will serve patients and deliver growth,” said Richard A. Gonzalez,Chairman of the Board and Chief Executive Officer, AbbVie. “With those assetsand a relentless focus on innovation we intend to create significant value forour shareholders.”

Strong, Well-Managed Business and Product Portfolio

AbbVie isnavigated by a team of experienced senior leaders who understand how to manageAbbVie for long-term, profitable growth and who have the proven ability tocommercialize scientific discoveries for patients. As a biopharmaceuticalcompany, AbbVie has adopted a streamlined and focused business model built on abroad portfolio of market leading medicines that will enable AbbVie to investin tomorrow’s therapies.

Theportfolio includes both growth brands and durable performers, including HUMIRA,AndroGel, Lupron, Synagis,Creon, Synthroid, Kaletra, Norvir and Zemplar.

Relatedinformation: www.abbvieinvestor.com